TOMORROW´S HEALTHCARE, TODAY

EpiDisease SL is an innovative Spanish biotechnology company that has positioned itself as a pioneer in the research and development of clinical tools based on genetic and epigenetic advances. With over 10 years of dedication and effort, EpiDisease SL is committed to offering solutions that deliver the healthcare of the future, today. Its flagship product, ScoliGEN, is a clear example of its scientific and cutting-edge work, providing a test that enables more precise and personalized management of children with AIS.
At EpiDisease, science and health come together to transform medical care and provide patients with the best opportunities for their well-being.
At EpiDisease SL, we are excited to announce our collaboration with Grupo IHP to offer cutting-edge in vitro diagnostic (IVD) tools: ScoliGEN and ScoliMIR. These innovative solutions, developed after 10 years of research and development, are specifically designed for patients with Adolescent Idiopathic Scoliosis (AIS) and their families. The availability of ScoliGEN and ScoliMIR at the Grupo IHP Specialty Center represents a global milestone in the integration of genetics and epigenetics into scoliosis management. These tools enable a precision and personalized approach, providing physicians with valuable information that can guide clinical decisions and improve outcomes and quality of life for children affected by this condition, and their families.
The Spine Team at IHP

Dr. David M. Farrington holds a degree in Medicine and Surgery from the University of Seville.

He later specialized in Orthopedic Surgery and Traumatology at the Valme University Hospital, where he practiced for several years until 2003, when he joined the San Juan de Dios Hospital of Aljarafe as Head of the Orthopedic Surgery and Traumatology Department.

In 2006, he joined the Virgen del Rocío Hospital as head of the Pediatric Orthopedics Unit, where he served as Section Chief until 2017.

Currently, he is head of the Pediatric Orthopedics Unit at QuirónSalud Sagrado Corazón Hospital (Seville) and a member of the Orthopediátrica team, an entity specialized in pediatric orthopedic and trauma care within the IHP group.

Passionate about pediatric orthopedics, he has dedicated the last 15 years of his professional career primarily to the field of spinal deformities during childhood. He recently launched the PediSpine program, which aims to offer pediatric patients with spinal problems a novel and multidisciplinary approach.

  • Degree in Medicine and Surgery from the University of Seville
  • Specialist in Orthopedic Surgery and Traumatology
  • Head of the Pediatric Orthopedics Unit at Virgen del Rocío University Hospital in Seville from 2007 to 2017
  • Training stays at: Morgan Stanley Children’s Hospital (New York), Children’s Hospital of Philadelphia, Rady Children’s Hospital (San Diego), Hospital for Joint Diseases (New York), and Mayo Clinic (Rochester)
  • Founding member of the Spanish Society of Pediatric Orthopedics and its president from 2018 to 2021
  • Only Spanish member of the International Pediatric Orthopedic Think Tank
  • Member of the Scoliosis Research Society
What are ScoliGEN and ScoliMIR?
ScoliGEN: This genetic tool assesses the genetic profile, identifying variants that may influence the progression of scoliosis. With this information, physicians can personalize treatment plans for each child and more effectively plan how the condition may evolve.
More info about ScoliGEN
Informed Consent
Patient Information
ScoliGEN is currently available
Buy ScoliGEN
ScoliMIR: This epigenetic tool provides information on how environmental and lifestyle factors can affect gene expression related to scoliosis. With this information, physicians can diagnose and predict the evolution of the spine, as well as monitor the effectiveness of conservative interventions—adapting, optimizing, and personalizing their approach for each case.
More info about ScoliGEN
Informed Consent
Patient Information
ScoliMIR is currently undergoing regulatory review. It is expected to be commercially available for patients in the fourth quarter of 2024.
Buy ScoliGEN
A Personalized Approach for Each Patient
The collaboration between EpiDisease SL and IHP Hospitals not only represents an advancement in medical technology, but also reflects our shared commitment to improving the quality of life for young people with AIS. By bringing the power of genetics and epigenetics into treatment, we are empowering physicians and families to make informed, data-driven decisions. We are excited about the future and the positive impact that ScoliGEN and ScoliMIR will have on the lives of patients and their families. Together, we are paving the way for a more effective and personalized approach to managing adolescent idiopathic scoliosis. For more information on how these tools can benefit your family, feel free to contact the PediSpine Unit at IHP Hospital.